References
- Afrakhteh M, Khodakarami N, Moradi A, et al (2007). A study of 13315 papanicolau smear diagnoses in shohada hospital. J Family Reprod Health, 1, 74-78.
- Andrae B, Kemetli L, Sparen P, et al (2008). Screeningpreventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst, 100, 622-29. https://doi.org/10.1093/jnci/djn099
- Andres-Gamboa O, Chicaiza L, Garcia-Molina M, et al (2008). Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex, 50, 276-85. https://doi.org/10.1590/S0036-36342008000400005
- Anttila A, Pukkala E, Soderman B, et al (1999). Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer, 83, 59-65. https://doi.org/10.1002/(SICI)1097-0215(19990924)83:1<59::AID-IJC12>3.0.CO;2-N
- Arab M, Noghabaei G, Kazemi SN (2014). Comparison of crude and age-specific incidence rates of breast, ovary, endometrium and cervix cancers in Iran, 2005. Asian Pac J Cancer Pre, 15, 2461. https://doi.org/10.7314/APJCP.2014.15.6.2461
-
Behtash N, Nazari Z, Khaniki M, et al (2008). Liqui
$prep^{TM}$ a new liquid based cervical cytology method in comparison with conventional Pap smear in developing counteries. ResJ Biological Sciences, 3, 627-30. - Berkhof J, Coupe VM, Bogaards JA, et al (2010). The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer, 127, 2147-58. https://doi.org/10.1002/ijc.25211
- Bosch F, Munoz N, De Sanjose S, et al (1993). Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev, 2, 415-22.
- Burr J M, Mowatt G, Hernandez R A, et al. (2007). The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technology Assessment 2007, 11, 41.
- Center for Disease Control and Prevention Noncomunicable Diseases Unit Cancer Office. (2012). Iranian annual of national cancer registration report 2009-2010 [Online]. Iran.
- Chalkidou K, Marquez P, Dhillon PK, et al (2014). Evidenceinformed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol, 15, 119-31. https://doi.org/10.1016/S1470-2045(13)70547-3
- Chawla PC, Chawla AK, Shrivastava R, et al (2014). Situation analysis of existing facilities for screening, treatment and prevention of cervical cancer in hospitals/primary health centers of delhi-NCR Region, India. Asian Pac J Cancer Prev, 15, 5475. https://doi.org/10.7314/APJCP.2014.15.13.5475
- Chow IH, Tang C, You S, et al (2010). Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer, 103, 1773-82. https://doi.org/10.1038/sj.bjc.6605974
- Chuck A (2010). Cost Effectiveness of 21 alternative cervical cancer screening strategies. Value in Health, 13, 169-79. https://doi.org/10.1111/j.1524-4733.2009.00611.x
- De Kok I M, Van Rosmalen J, Dillner J, et al (2012). Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ: British Medical Journal, 344, 1-14.
- Doshmangir L, Rashidian a, Akbari Sari A. (2011). Unresolved issues in medical tariffs: Challenges and respective solutions to improve tariff system in Iranian health sectors. Hospital J, 10, 2-10.
- Dzuba I G, Diaz E Y, Allen B, et al (2002). The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med, 11, 265-75. https://doi.org/10.1089/152460902753668466
- Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base Lyon, France: International Agency for Research on Cancer.
- Forman D, Bray F, Brewster D, et al (2013). Cancer incidence in five continents, Vol. X (electronic version). Lyon, IARC.
- Franco El, Duarte-Franco E, Ferenczy L, et al (2001). Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J, 164, 1017-25.
- Gakidou E, Nordhagen S, Obermeyer Z (2008). Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med, 5, 132. https://doi.org/10.1371/journal.pmed.0050132
- Khodakarami N, Clifford GM, Yavari P, et al (2012). Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. Int J Cancer, 131, 156-61. https://doi.org/10.1002/ijc.26488
- Khorasanizadeh F, Hassanloo J, Khaksar N, et al (2013). Epidemiology of cervical cancer and human papilloma virus infection among Iranian women-Analyses of national data and systematic review of the literature. Gynecol Oncol, 128, 277-81. https://doi.org/10.1016/j.ygyno.2012.11.032
- Kuhn L, Denny L, Pollack A, et al (2000). Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Nat Cancer Inst, 92, 818-25. https://doi.org/10.1093/jnci/92.10.818
- Mahlck C, Jonsson H, Lenner P (1994). Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynecol Obstetrics, 44, 267-72. https://doi.org/10.1016/0020-7292(94)90177-5
- Malloy C, Sherris J, Herdman C (2000). HPV DNA Testing: Technical and Programmatic. Seattle, Washington, Program for Appropriate Technology in Health [http://www.popline.org], 2000 Dec. 27 p.
- Nabandith V, Pholsena V, Mounthisone P, et al (2012). First trial of cervical cytology in healthy women of urban Laos using by self-sampling instrument. Asian Pac J Cancer Prev, 13, 4665-67. https://doi.org/10.7314/APJCP.2012.13.9.4665
- Partridge EE, Abu-Rustum NR, Campos SM, et al (2010). Cervical cancer screening. J Natl Compr Canc Netw, 8, 1358-86.
- Pity I S, Shamdeen M Y ,Wais S A (2012). Follow up of atypical squamous cell Pap Smears in Iraqi women. Asian Pac J Cancer Prev, 13, 3455-60. https://doi.org/10.7314/APJCP.2012.13.7.3455
- R. N. (2014). FDA OKs HPV DNA Test for Primary Cervical Cancer Screening [Online]. Available: http://www.medscape.com/viewarticle/824114 [Accessed 24 April 2014].
- Ries L, Eisner M, Kosary C, et al (2002). SEER Cancer Statistics Review, 1973-1999, National Cancer Institute. Bethesda, MD. Table VI-1. Available from URL: http://seer. cancer. gov/csr/1973_1999.
- Sankaranarayanan R, Budukh A M ,Rajkumar R (2001). Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bull WHO, 79, 954-62.
- Saxena U, Sauvaget C ,Sankaranarayanan R (2012). Evidencebased screening, early diagnosis and treatment strategy of cervical cancer for national policy in low-resource countries: example of India. Asian Pac J Cancer Prev, 13, 1699-703. https://doi.org/10.7314/APJCP.2012.13.4.1699
- Sengul D, Altinay S, Oksuz H, et al (2014). Population-based cervical screening outcomes in Turkey over a period of approximately nine and a half years with emphasis on results for women aged 30-34. Asian Pac J Cancer Prev: APJCP, 15, 2069. https://doi.org/10.7314/APJCP.2014.15.5.2069
- Shi JF, Canfell K, Lew JB, et al (2011). Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer, 11, 239. https://doi.org/10.1186/1471-2407-11-239
- Tanprasertkul C, Sritipsukno P (2010). HPV DNA testing for cervical cancer screening: a systematic review and metaanalysis. Thammasat Medical J, 9, 15-25.
- Treatment. M O H a M E I D O (2010). Diagnostic and treatment service tariffs in public and private sectors in 2010, Teheran, Rahavard
- Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
- Wang JL, Yang YZ, Dong WW, et al (2013). Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev, 14, 2979-82. https://doi.org/10.7314/APJCP.2013.14.5.2979
- World B (2012). World development indicators 2012, world bank publications.
- Zendehdel K, Sedighi Z, Hasanlou Z, Nahvijou A (2010). Improving quality of cancer registration in Iran. Part1: evaluation and comparison of cancer registration results in the country. HAKIM.
Cited by
- Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer vol.11, pp.6, 2016, https://doi.org/10.1371/journal.pone.0156705